This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
McLaughlin S , Mittendorf EA , Bleicher RJ , McCready DR , King TA
The 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: MRI in breast cancer: where are we now?
Ann Surg Oncol. 2014 Jan;21(1) :28-36
PMID: 24145992 URL: https://www.ncbi.nlm.nih.gov/pubmed/24145992
AbstractMagnetic resonance imaging (MRI) has been widely applied in the contemporary management of patients with breast cancer and as a screening tool for those at increased risk; however, prospective evidence that the use of breast MRI improves patient outcomes remains limited to screening of known BRCA mutation carriers or women at increased risk based on a strong family history. Despite this, the role of MRI in the routine evaluation of the newly diagnosed breast cancer patient remains a subject of much debate, with widely divergent views on the value of MRI in selecting local therapy. The application of MRI in patients undergoing neoadjuvant therapy is an area of active investigation, with several potential benefits, including predicting response to therapy. We review the current state of the literature on the topics of MRI for screening, MRI and short-term surgical outcomes, MRI and long-term surgical outcomes, and MRI and neoadjuvant chemotherapy as presented at the 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium, 9 March 2013.
NotesMcLaughlin, Sarah Mittendorf, Elizabeth A Bleicher, Richard J McCready, David R King, Tari A eng Ann Surg Oncol. 2014 Jan;21(1):28-36. doi: 10.1245/s10434-013-3307-9. Epub 2013 Oct 22.